

# SCREENING FOR KIDNEY DISEASES IN THE CAMP: WHICH TOOLS FOR THE BEST EFFICIENCY?

**Pierre Delanaye, MD, PhD**

Nephrology Dialysis and Transplantation

University of Liège

CHU Sart Tilman

Liège

BELGIUM

# Conflict of interest

- I have no conflict of interest to declare
- I am nephrologist and my area of expertise is CKD epidemiology, GFR estimation and measurement
- I have no experience in humanitarian medicine
- I thank my friend, Dr Jean-Paul Jemmy, who helped me for this presentation

# SCREENING FOR KIDNEY DISEASES IN THE CAMP: WHICH TOOLS FOR THE BEST EFFICIENCY?

**Pierre Delanaye, MD, PhD**

Nephrology Dialysis and Transplantation

University of Liège

CHU Sart Tilman

Liège

BELGIUM

# SCREENING FOR **KIDNEY DISEASES** IN THE CAMP: WHICH TOOLS FOR THE BEST EFFICIENCY?

**Pierre Delanaye, MD, PhD**

Nephrology Dialysis and Transplantation

University of Liège

CHU Sart Tilman

Liège

BELGIUM

# Where? Why? Who?

- Acute kidney Injury

Most of the time AKI is associated with other diseases, especially in all diseases with a risk of dehydration (especially if dryness)

AKI due to rhabdomyolysis in the context of earthquake

- Chronic Kidney Disease

The silent killer

5 to 10% of the population

Diabetes

Each year, we welcome refugees with end stage renal diseases

# Renal replacement therapy for refugees with end-stage kidney disease: an international survey of the nephrological community



Wim Van Biesen<sup>1,2</sup>, Raymond Vanholder<sup>1,2,3</sup>, Bert Vanderhaegen<sup>4,5</sup>, Norbert Lameire<sup>1,2</sup>, Christoph Wanner<sup>6,7</sup>, Andrzej Wiecek<sup>6,8</sup>, Mehmet S. Sever<sup>2,9</sup>, Johan Feehally<sup>10,11</sup>, Remuyza Kazancioglu<sup>10,12</sup>, Eric Rondeau<sup>10,13</sup>, Adeera Levin<sup>10,14</sup> and David Harris<sup>10,15</sup>

<sup>1</sup>Renal Division, Ghent University Hospital, Ghent, Belgium; <sup>2</sup>Renal Disaster Relief Task Force (RDRTF), International Society of Nephrology, Ghent, Belgium; <sup>3</sup>European Kidney Health Alliance, Brussels, Belgium; <sup>4</sup>Hospital and Research Ethics Committee, Ghent University Hospital, Ghent, Belgium; <sup>5</sup>Centre for Ethics in Medicine, University of Bristol, Bristol, UK; <sup>6</sup>European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), Parma, Italy; <sup>7</sup>Renal Division, University Hospital of Würzburg, Würzburg, Germany; <sup>8</sup>Department of Nephrology, Transplantation and Internal Medicine Medical University of Silesia, Katowice, Poland; <sup>9</sup>Department of Nephrology, Istanbul School of Medicine, Istanbul, Turkey; <sup>10</sup>The International Society of Nephrology, Brussels, Belgium; <sup>11</sup>Department of Nephrology, Leicester General Hospital, Leicester, UK; <sup>12</sup>Department of Nephrology, School of Medicine, Bezmialen Vakif University, Istanbul, Turkey; <sup>13</sup>Renal Division, Assistance Publique-Hôpitaux de Paris, Tenon Hospital, Paris, France; <sup>14</sup>Division of Nephrology, University of Columbia, Vancouver, British Columbia, Canada; and <sup>15</sup>Sydney Medical School—Westmead University of Sydney, Westmead Hospital, Sydney, Australia

*Kidney International Supplements* (2016) **6**, 35–41.

**Table 1 | Geographic origin of respondents, with numbers of refugees on dialysis, by country**

Region	Country (centers [n], refugees on dialysis in preceding 4 months [n])
Central and Eastern Europe	Albania (2, 2), Bulgaria (2, 0), Croatia (2, 0), Czech Republic (6, 0), Estonia (1, 0), Hungary (1, 1), Lithuania (6, 0), Macedonia (2, 2), Poland (2, 0), Romania (12, 0), Serbia (2, 8), Slovenia (4, 1), Turkey (23, 121)
Southern Europe	Greece (17, 22), Italy (13, 3), Portugal (1, 0), Spain (15, 3)
Middle East	Israel (5, 1), Iran (7, 6), Iraq (2, 30), Jordan (1, 0), Kuwait (1, 9), Lebanon (3, 31), Saudi Arabia (5, 20), United Arab Emirates (3, 1), Yemen (1, 80)
North Africa	Algeria (1, 2), Egypt (7, 0), Morocco (4, 0), Tunisia (3, 0)
North America	Canada (1, 0)
Scandinavian Europe	Denmark (3, 2), Finland (2, 0), Norway (1), Sweden (20, 32)
Western Europe	Austria (3, 3), Belgium (20, 67), France (15, 61), Germany (14, 28), Ireland (2, 0), Luxembourg (1, 0), Scotland (1, 0), Switzerland (17, 33), The Netherlands (27, 28), United Kingdom (18, 113)

ESRD: how many die on the way to Europe???



**Table 2 | Staging of AKI**

Stage	Serum creatinine	Urine output
1	1.5–1.9 times <b>baseline</b> OR ≥ 0.3 mg/dl (≥ 26.5 μmol/l) increase	< 0.5 ml/kg/h for 6–12 hours
2	2.0–2.9 times baseline	< 0.5 ml/kg/h for ≥ 12 hours
3	3.0 times baseline OR Increase in serum creatinine to ≥ 4.0 mg/dl (≥ 353.6 μmol/l) OR Initiation of renal replacement therapy OR, In patients < 18 years, decrease in eGFR to < 35 ml/min per 1.73 m <sup>2</sup>	< 0.3 ml/kg/h for ≥ 24 hours OR Anuria for ≥ 12 hours

**Prognosis of CKD by GFR and albuminuria categories: KDIGO 2012**


GFR categories (ml/min/1.73 m <sup>2</sup> ) Description and range	Persistent albuminuria categories Description and range		
	A1	A2	A3
	Normal to mildly increased < 30 mg/g < 3 mg/mmol	Moderately increased 30–300 mg/g 3–30 mg/mmol	Severely increased > 300 mg/g > 30 mg/mmol
<b>G1</b> Normal or high ≥ 90			
<b>G2</b> Mildly decreased 60–89			
<b>G3a</b> Mildly to moderately decreased 45–59			
<b>G3b</b> Moderately to severely decreased 30–44			
<b>G4</b> Severely decreased 15–29			
<b>G5</b> Kidney failure < 15			

REVIEW [www.jasn.org](http://www.jasn.org)

**CKD: A Call for an Age-Adapted Definition**

Pierre Delanaye<sup>1</sup>, Kitty J. Jager<sup>2</sup>, Arend Bökenkamp<sup>3</sup>, Anders Christensson<sup>4</sup>, Laurence Dubourg<sup>5</sup>, Bjørn Odvar Eriksen<sup>6,7</sup>, François Gaillard<sup>8</sup>, Giovanni Gambaro<sup>9</sup>, Markus van der Giet<sup>10</sup>, Richard J. Glassock<sup>11</sup>, Olafur S. Indridason<sup>12</sup>, Marco van Londen<sup>13</sup>, Christophe Mariat<sup>14</sup>, Toralf Melsom<sup>6,7</sup>, Olivier Moranne<sup>15</sup>, Gunnar Nordin<sup>16</sup>, Runolfur Palsson<sup>12,17</sup>, Hans Pottel<sup>18</sup>, Andrew D. Rule<sup>19</sup>, Elke Schaeffner<sup>20</sup>, Maarten W. Taal<sup>21</sup>, Christine White<sup>22</sup>, Anders Grubb<sup>23</sup>, and Jan A. J. G. van den Brand<sup>24</sup>

J Am Soc Nephrol. 2019 Oct;30(10):1785-1805.



**Figure 3.** Age-specific thresholds in relation to age-specific GFR percentiles. GFR cut-off values and percentiles according to age (here percentiles of eGFR are calculated using the FAS equation). The bold line represents an age-adapted threshold for CKD: 75 ml/min per 1.73 m<sup>2</sup> for age below 40 years, 60 ml/min per 1.73 m<sup>2</sup> for age between 40 and 65 years, and 45 ml/min per 1.73 m<sup>2</sup> for age above 65 years. The dashed line represents the median (50th percentile) and the thin solid lines represent the 97.5th and 2.5th percentiles. The shaded zone is considered as below the normal reference intervals for GFR (<2.5th percentile).

RESEARCH ARTICLE

Open Access


# Prevalence and care-seeking for chronic diseases among Syrian refugees in Jordan



Shannon Doocy<sup>1\*</sup>, Emily Lyles<sup>1</sup>, Timothy Robertson<sup>1</sup>, Laila Akhu-Zaheya<sup>2</sup>, Arwa Oweis<sup>2</sup> and Gilbert Burnham<sup>1</sup>

- 1550 Syrian refugees in Jordan
- Survey about HTA, CV diseases, diabetes, COPD, arthritis





**Fig. 3** Age specific prevalence rates of chronic health conditions

# SCREENING FOR KIDNEY DISEASES IN THE CAMP: WHICH TOOLS FOR THE BEST EFFICIENCY?

**Pierre Delanaye, MD, PhD**

Nephrology Dialysis and Transplantation

University of Liège

CHU Sart Tilman

Liège

BELGIUM

# SCREENING FOR KIDNEY DISEASES IN THE CAMP: WHICH **TOOLS** FOR THE BEST EFFICIENCY?

**Pierre Delanaye, MD, PhD**

Nephrology Dialysis and Transplantation

University of Liège

CHU Sart Tilman

Liège

BELGIUM

# SCREENING FOR KIDNEY DISEASES IN THE CAMP: WHICH **TOOLS** FOR THE BEST **EFFICIENCY?**

**Pierre Delanaye, MD, PhD**

Nephrology Dialysis and Transplantation

University of Liège

CHU Sart Tilman

Liège

BELGIUM

# Serum creatinine: Point of care (POC)

- Not in every situation...
- Before CT-Scan with contrast (as an example)
- Certainly in humanitarian situations...



Contents lists available at ScienceDirect

Clinica Chimica Acta

journal homepage: [www.elsevier.com/locate/cca](http://www.elsevier.com/locate/cca)



## Estimated glomerular filtration rate using a point of care measure of creatinine in patients with iohexol determinate GFR



Violeta Stojkovic<sup>a,\*</sup>, Pierre Delanaye<sup>b</sup>, Gregory Collard<sup>a</sup>, Nunzio Ferrante<sup>a</sup>, Caroline Le Goff<sup>a</sup>, Laurence Lutteri<sup>a</sup>, Etienne Cavalier<sup>a</sup>

<sup>a</sup> Department of Clinical Chemistry, University of Liège, CHU Sart-Tilman, 4000 Liège, Belgium


<sup>b</sup> Nephrology, Dialysis, Transplantation, University of Liège, CHU Sart-Tilman, 4000 Liège, Belgium




- Creatinine measured with Enzymatic assay (Roche Cobas)
- Creatinine measured by POC capillary (StatSensor, Nova Medical)
- GFR estimated by the CKD-EPI<sub>2009</sub> equation
- GFR measured by iohexol plasma clearance
- 120 subjects,  $52 \pm 13$  years, 49% of women, mean mGFR was  $77 \pm 27$  mL/min/1.73m<sup>2</sup> (29 patients with mGFR < 60 mL/min/1.73m<sup>2</sup>)

# Statistics

- Good correlation: a “*sine qua non*” condition but insufficient
- Bias: mean difference between two values = the systematic error
- Precision: SD around the bias = the random error
- Accuracy 30% = % of eGFR between  $\pm 30\%$  of measured GFR






Passing-Bablok: Creatinine (POC)=1.02 x Creatinine (Cobas) – 0.07  
95% CI: 0.93 to 1.15 for slope  
–0.20 to 0.020 for intercept



POC



Cobas




Fig. 2. (A) Bland-Altman chart of the eGFR (mL/min/1.73m<sup>2</sup>) obtained with the POC (Statsensor) in comparison to mGFR (mL/min/1.73m<sup>2</sup>). (B) Bland-Altman chart of the eGFR (mL/min/1.73m<sup>2</sup>) obtained with the Cobas 8000 in comparison to mGFR (mL/min/1.73m<sup>2</sup>).

Accuracy within 30%:

81% POC

95% Cobas

(p=0,0017)




Fig. 3. Concordance of eGFR ( $\text{mL}/\text{min}/1.73\text{m}^2$ ) obtained with Statsensor with mGFR ( $\text{mL}/\text{min}/1.73\text{m}^2$ ) for categorizing CKD stages.

Zone of concordance calculated at 58% (70/120).

Zone of concordance calculated at 63% (76/120) with Cobas



Sean Currin\*, Mwawi Gondwe, Nokthula Mayindi, Shingirai Chipungu, Bongekile Khoza, Lungile Khambule, Tracy Snyman, Stephen Tollman, June Fabian and Jaya George, on behalf of the ARK Consortium

# Evaluating chronic kidney disease in rural South Africa: comparing estimated glomerular filtration rate using point-of-care creatinine to iohexol measured GFR

Clin Chem Lab Med. 2021 Mar 15;59(8):1409-1420.



- Creatinine measured with kinetic Jaffe assay (Roche Cobas)
- Creatinine measured by POC (StatSensor capillary and venous, Nova Medical and iSTAT, Abbott)
- GFR estimated by the CKD-EPI<sub>2009</sub> equation
- GFR measured by iohexol plasma clearance
- N=674, 43 ± 14 years, 59% of women, mean mGFR was 81 ± 24 mL/min/1.73m<sup>2</sup> (134 patients with mGFR < 60 mL/min/1.73m<sup>2</sup>)




Sean Currin\*, Mwawi Gondwe, Nokthula Mayindi, Shingirai Chipungu, Bongekile Khoza, Lungile Khambule, Tracy Snyman, Stephen Tollman, June Fabian and Jaya George, on behalf of the ARK Consortium

# Evaluating chronic kidney disease in rural South Africa: comparing estimated glomerular filtration rate using point-of-care creatinine to iohexol measured GFR


Clin Chem Lab Med. 2021 Mar 15;59(8):1409-1420.




- Creatinine measured with **kinetic Jaffe** assay (Roche Cobas)
- Creatinine measured by POC (StatSensor capillary and venous, Nova Medical and iSTAT, Abbott)
- GFR estimated by the CKD-EPI<sub>2009</sub> equation
- GFR measured by iohexol plasma clearance
- N=674, 43 ± 14 years, 59% of women, mean mGFR was 81 ± 24 mL/min/1.73m<sup>2</sup> (134 patients with mGFR < 60 mL/min/1.73m<sup>2</sup>)



Passing-Bablok: Creatinine (POC)=1.45 x  
Creatinine (Cobas) – 7,68  
95% CI: 1,33 to 1.57 for slope  
–14,43 to -1,33 for intercept



Passing-Bablok: Creatinine (POC)=1.16 x  
Creatinine (Cobas) + 0,16  
95% CI: 1,13 to 1.20 for slope  
–2,2 to -2,13 for intercept







Passing-Bablok: Creatinine (POC)=1.17 x  
Creatinine (Cobas) +6,50  
95% CI: 1,03 to 1.33 for slope  
–2,33 to 14,58 for intercept





StatSensor® capillary  
+ iohexol mGFR  
n= 670

iSTAT®  
+ iohexol mGFR  
n= 667

StatSensor® venous  
+ iohexol mGFR  
n= 214



The percentage of total samples correctly classified into the eGFR groups of <60, 60–89 and >90 mL/min/1.73 m<sup>2</sup> ranged from 41.7% (95% CI: 38.0–45.6) to 52.8% (95% CI: 45.9–59.7).



The percentage of total samples correctly classified into the eGFR groups of <60, 60–89 and >90 mL/min/1.73 m<sup>2</sup> ranged from 41.7% (95% CI: 38.0–45.6) to 52.8% (95% CI: 45.9–59.7).

The POC creatinine eGFR equations correctly classified more samples into the correct eGFR groups than the respective laboratory creatinine equations

- The limitations of eGFR = equations (not the POC)
- We can expect an accuracy within 30% of 85-90% with creatinine based-equations (and less in Africa)
- Other POCs methods are available





StatSensor® et StatSensor Xpress™



Clinica Chimica Acta 497 (2019) 13–19

Contents lists available at ScienceDirect

Clinica Chimica Acta

journal homepage: [www.elsevier.com/locate/cca](http://www.elsevier.com/locate/cca)



Analytical and clinical performance of three hand-held point-of-care creatinine analyzers for renal function measurements prior to contrast-enhanced imaging



Catharina van der Heijden<sup>a</sup>, Laurence Roosens<sup>b</sup>, Hugo Cluckers<sup>a</sup>, Anaryllis H. Van Craenenbroeck<sup>b,c,d</sup>, Bart Peeters<sup>a</sup>\*

<sup>a</sup>Antwerp University Hospital, Laboratory Medicine, Wilrijkstraat 10, 2650 Edingen, Belgium

<sup>b</sup>Antwerp University Hospital, Nephrology, Wilrijkstraat 10, 2650 Edingen, Belgium

<sup>c</sup>Laboratory of Experimental Medicine and Pharmacology, University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium

<sup>d</sup>University Hospital Leuven, Department of Nephrology, Herestraat 49, 3000 Leuven, Belgium



## The i-STAT System

 **Abbott**  
Point of Care



**SIEMENS**  
Healthineers 

# Don't forget...

- Logistics, power, maintenance
- Skills transfer
- Costs...
- Is it used?

## Renal Disaster Relief Task Force in Haiti earthquake

*Raymond Vanholder, \*Noel Gibney,  
Valerie A Luyckx, Mehmet S Sever, for  
the Renal Disaster Relief Task Force*  
[ngibney@ualberta.ca](mailto:ngibney@ualberta.ca)

Departments of Internal Medicine and Nephrology,  
University Hospital, Ghent, Belgium (RV); Division  
of Critical Care Medicine (NG) and Division of  
Nephrology (VAL), University of Alberta, Edmonton,  
AB T6G 2B7, Canada; and Departments of Internal  
Medicine and Nephrology, Istanbul School of  
Medicine, Istanbul, Turkey (MSS)

[www.thelancet.com](http://www.thelancet.com) Vol 375 April 3, 2010



AFP/Getty Images

- iSTAT used (because creatinine but also potassium)
- « hyper specialised » intervention

# In camps of Refugees

- Depends on the situation and on the deployment
- Ebola or severe earthquakes: important deployment by different national or international organizations (USAID, BeFast, etc) => they come (and leave) with their own laboratories
- Syrian refugees in Jordan => the country has the ability to use their own laboratories (or gas analyzers)
- Syrian refugees in Syria: POC will be used
- But it is costly, not available locally
- It is just conceivable if logistical and financial support (NGO)

# Which estimating equations to be used?

- Cockcroft
- MDRD
- CKD-EPI
- EKFC

# Cockcroft Vs MDRD Vs CKD-EPI

	Cockcroft	MDRD	CKD-EPI
<b>Population</b>	Canada 1976	USA 1999	« International » 2009
<b>N</b>	249	1628	5504+2750+3896
<b>Mean GFR</b>	73	40	68
<b>GFR</b>	Creatinine clearance	Iothalamate	Diverse
<b>Assay</b>	« Jaffe »	Jaffe calibrated	Jaffe calibrated
<b>% women</b>	4	40	43-45%
<b>% black</b>	0 (?)	12	10-32%
<b>Mean age</b>	18-92	51	47-50
<b>Mean weight</b>	72	79.6	79-82
<b>BSA indexation</b>	No	Yes	Yes
<b>Internal Validation</b>	No	Yes	Yes

Cockcroft DW, *Nephron*, 1976, 16, p31  
 Levey AS, *Ann Intern Med*, 1999, 130, p461  
 Levey AS, *Ann Intern Med*, 2009, p604



*Ann Intern Med.* 2021;174:183-191.

**Annals of Internal Medicine**

ORIGINAL RESEARCH

## **Development and Validation of a Modified Full Age Spectrum Creatinine-Based Equation to Estimate Glomerular Filtration Rate**

### **A Cross-sectional Analysis of Pooled Data**

Hans Pottel, PhD\*; Jonas Björk, PhD\*; Marie Courbebaisse, MD, PhD; Lionel Couzi, MD, PhD; Natalie Ebert, MD, MPH; Björn O. Eriksen, MD, PhD; R. Neil Dalton, PhD; Laurence Dubourg, MD, PhD; François Gaillard, MD, PhD; Cyril Garrouste, MD; Anders Grubb, MD, PhD; Lola Jacquemont, MD, PhD; Magnus Hansson, MD, PhD; Nassim Kamar, MD, PhD; Edmund J. Lamb, PhD; Christophe Legendre, MD; Karin Littmann, MD; Christophe Mariat, MD, PhD; Toralf Melsom, MD, PhD; Lionel Rostaing, MD, PhD; Andrew D. Rule, MD; Elke Schaeffner, MD, PhD, MSc; Per-Ola Sundin, MD, PhD; Stephen Turner, MD, PhD; Arend Bökenkamp, MD; Ulla Berg, MD, PhD; Kajsa Åsling-Monemi, MD, PhD; Luciano Selistre, MD, PhD; Anna Åkesson, BSc; Anders Larsson, MD, PhD; Ulf Nyman, MD, PhD†; and Pierre Delanaye, MD, PhD†

- Subjects with measured GFR and standardized creatinine
- 11,251 development and internal validation
- 8,378 external validation
- 1,254 aged between 2 to 18 years
- 7 + 6 cohorts
- Only White people

**Figure 1.** The new EKFC equation.

Age	SCr/Q	Equation
2–40 y	<1	$107.3 \times (\text{SCr}/\text{Q})^{-0.322}$
	$\geq 1$	$107.3 \times (\text{SCr}/\text{Q})^{-1.132}$
>40 y	<1	$107.3 \times (\text{SCr}/\text{Q})^{-0.322} \times 0.990^{(\text{Age} - 40)}$
	$\geq 1$	$107.3 \times (\text{SCr}/\text{Q})^{-1.132} \times 0.990^{(\text{Age} - 40)}$

#### Q Values

For ages 2–25 y:

Males:

$$\ln(Q) = 3.200 + 0.259 \times \text{Age} - 0.543 \times \ln(\text{Age}) - 0.00763 \times \text{Age}^2 + 0.0000790 \times \text{Age}^3$$

Females:

$$\ln(Q) = 3.080 + 0.177 \times \text{Age} - 0.223 \times \ln(\text{Age}) - 0.00596 \times \text{Age}^2 + 0.0000686 \times \text{Age}^3$$

For ages >25 y:

Males:

$$Q = 80 \mu\text{mol/L} (0.90 \text{ mg/dL})$$


Females:

$$Q = 62 \mu\text{mol/L} (0.70 \text{ mg/dL})$$

SCr and Q in  $\mu\text{mol/L}$  (to convert to mg/dL, divide by 88.4)

Q values (in  $\mu\text{mol/L}$  or mg/dL) correspond to the median SCr values for the age- and sex-specific populations. EKFC = European Kidney Function Consortium; SCr = serum creatinine.





MDRD

$$\text{GFR} = 175 \times (\text{Scr})^{-1.154} \times (\text{Age})^{-0.203} \times (0.742 \text{ if female}) \times (1.212 \text{ if African American})$$

+21%

CKD-EPI  
2009

$$\text{GFR} = 141 \times \min(\text{Scr}/\kappa, 1)^\alpha \times \max(\text{Scr}/\kappa, 1)^{-1.209} \times 0.993^{\text{Age}} \times (1.018 \text{ if female}) \times (1.159 \text{ if African American})$$

+16%

\*S<sub>cr</sub> is serum creatinine in mg/dL  
κ is 0.7 for females and 0.9 for males  
α is -0.329 for females and -0.411 for males  
min indicates the minimum of S<sub>cr</sub>/κ or 1  
max indicates the maximum of S<sub>cr</sub>/κ or 1

# A new creatinine-based CKD-EPI equation

*The NEW ENGLAND JOURNAL of MEDICINE*

ORIGINAL ARTICLE

## New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race

L.A. Inker, N.D. Eneanya, J. Coresh, H. Tighiouart, D. Wang, Y. Sang, D.C. Crews, A. Doria, M.M. Estrella, M. Froissart, M.E. Grams, T. Greene, A. Grubb, V. Gudnason, O.M. Gutiérrez, R. Kalil, A.B. Karger, M. Mauer, G. Navis, R.G. Nelson, E.D. Poggio, R. Rodby, P. Rossing, A.D. Rule, E. Selvin, J.C. Seegmiller, M.G. Shlipak, V.E. Torres, W. Yang, S.H. Ballew, S.J. Couture, N.R. Powe, and A.S. Levey, for the Chronic Kidney Disease Epidemiology Collaboration\*












➤ [N Engl J Med. 2021 Nov 4;385\(19\):1737-1749.](#)

**Table 3.** Accuracy of Current and New Approaches for GFR Estimation as Compared with Measured GFR in the Validation Data Set.

Filtration Marker and Equation*		Black Participants	Non-Black Participants	Difference between Black Participants and Non-Black Participants (95% CI)†
Bias: Median Difference between Measured GFR and eGFR (95% CI)‡				
<i>milliliters per minute per 1.73 square meters</i>				
Creatinine				
eGFRcr(ASR), current	2009	-3.7 (-5.4 to -1.8)	-0.5 (-0.9 to 0.0)	-3.2 (-5.0 to -1.3)
eGFRcr(ASR-NB), new		7.1 (5.9 to 8.8)	-0.5 (-0.9 to 0.0)	7.6 (6.1 to 9.0)
eGFRcr(AS), new	2021	3.6 (1.8 to 5.5)	-3.9 (-4.4 to -3.4)	7.6 (5.6 to 9.5)
Creatinine				
eGFRcr(ASR), current	2009	85.1 (82.2 to 87.9)	89.5 (88.5 to 90.4)	-4.4 (-7.6 to -1.2)
eGFRcr(ASR-NB), new		86.4 (83.4 to 89.1)	89.5 (88.5 to 90.4)	-3.1 (-6.2 to 0)
eGFRcr(AS), new	2021	87.2 (84.5 to 90.0)	86.5 (85.4 to 87.6)	0.7 (-2.4 to 3.8)



# Performance of creatinine-based equations to estimate glomerular filtration rate in White and Black populations in Europe, Brazil and Africa


Pierre Delanaye <sup>1,2,\*</sup>, Emmanuelle Vidal-Petiot <sup>3,\*</sup>, Jonas Björk <sup>4,5</sup>, Natalie Ebert <sup>6</sup>, Björn O. Eriksen<sup>7</sup>, Laurence Dubourg<sup>8</sup>, Anders Grubb<sup>9</sup>, Magnus Hansson<sup>10</sup>, Karin Littmann<sup>11</sup>, Christophe Mariat<sup>12</sup>, Toralf Melsom<sup>7</sup>, Elke Schaeffner<sup>6</sup>, Per-Ola Sundin <sup>13</sup>, Arend Bökenkamp<sup>14</sup>, Ulla B. Berg<sup>15</sup>, Kajsa Åsling-Monemi<sup>15</sup>, Anna Åkesson<sup>4,5</sup>, Anders Larsson<sup>16</sup>, Etienne Cavalier <sup>17</sup>, R. Neil Dalton<sup>18</sup>, Marie Courbebaisse<sup>19</sup>, Lionel Couzi <sup>20</sup>, Francois Gaillard <sup>21</sup>, Cyril Garrouste<sup>22</sup>, Lola Jacquemont<sup>23</sup>, Nassim Kamar<sup>24</sup>, Christophe Legendre<sup>25</sup>, Lionel Rostaing <sup>26</sup>, Thomas Stehlé <sup>27,28</sup>, Jean-Philippe Haymann<sup>29</sup>, Luciano da Silva Selistre<sup>30</sup>, Jorge P. Strogoff-de-Matos <sup>31</sup>, Justine B. Bukabau<sup>32</sup>, Ernest K. Sumaili<sup>32</sup>, Eric Yayo<sup>33</sup>, Dagui Monnet<sup>33</sup>, Ulf Nyman<sup>34</sup>, Hans Pottel<sup>35,†</sup> and Martin Flamant<sup>36,†</sup>

**Table S3: Method and patients characteristics**  
Mean and SD of age and measured glomerular filtration


<b>White populations</b>									
Center	Country	Cohort	n	Method	Exogenous marker	Age	mGFR (mL/min/1.73m <sup>2</sup> )	Creatinine	% of female
Amsterdam	The Netherlands	CAPA-study <sup>5</sup> + referrals	48	Plasma clearance	Inulin	18.7±0.9	93.7±27.9	Enzymatic Roche	25.0
Berlin	Germany	BIS-Study <sup>6</sup>	657	Plasma clearance	Iohexol	78.4±6.1	60.3±21.5	Enzymatic Roche	41.7
France	France	Kidney Donor Study <sup>7</sup>	2,572	Plasma/renal clearance	Iohexol/ <sup>51</sup> Cr-EDTA/inulin	50.4±11.8	100.1±22.2	Varia <sup>7</sup>	61.9
Kent	UK	GFR in old adults <sup>8</sup>	394	Plasma clearance	Iohexol	80.4±4.6	55.3±20.5	Mass spectrometry	52.0
Leuven	Belgium	Referrals	21	Plasma clearance	<sup>51</sup> Cr-EDTA	19.1±1.2	78.2±23.1	Enzymatic Roche	47.6
Lund	Sweden	CAPA-study <sup>5</sup>	2,847	Plasma clearance	Iohexol	60.1±16.5	62.5±34.1	Enzymatic Abbott	48.5
Lyon	France	Referrals	2,435	Plasma/renal clearance	Iohexol/inulin	31.3±16.7	84.5±32.7	Jaffe and enzymatic Roche	46.8
Örebro	Sweden	Referrals	2,051	Plasma clearance	Iohexol	56.5±16.3	64.3±36.0	Enzymatic Roche and Ortho-Clinical	41.7
Saint-Etienne	France	HIV-study <sup>9</sup>	203	Plasma clearance	Iohexol	48.7±10.3	100.3±27.3	Enzymatic Ortho-Clinical	48.7
Stockholm	Sweden	Referrals	856	Plasma clearance	Iohexol	72.9±14.1	48.7±27.6	Jaffe Beckman Enzymatic Roche	44.2
Tromsø	Norway	RENIS-T6 study <sup>10</sup>	1,627	Plasma clearance	Iohexol	58.1±3.8	101.5±19.9	Enzymatic Roche	50.8
Rio de Janeiro	Brazil	Brazilian study <sup>12</sup>	39	Plasma clearance	<sup>51</sup> Cr-EDTA	60.0±13.5	41.9±23.4	Jaffe Roche	59.0
Paris	France	Referrals	3,465	Plasma clearance	<sup>51</sup> Cr-EDTA	52.4±14.8	61.3±26.6	Jaffe and Enzymatic Roche and Siemens	41.1
<b>Black population</b>									
Kinshasa/Abidjan	DRC/Côte d'Ivoire	African Study <sup>11</sup>	508	Plasma clearance	Iohexol	41.8±14.3	80.5±28.9	Enzymatic Roche	46.7
Rio de Janeiro	Brazil	Brazilian study <sup>12</sup>	61	Plasma clearance	<sup>51</sup> Cr-EDTA	55.9±13.8	49.8±32.2	Jaffe Roche	50.8
Paris	France	Referrals	964	Plasma clearance	<sup>51</sup> Cr-EDTA	50.4±13.8	61.1±24.6	Jaffe and Enzymatic Roche and Siemens	41.1

EKFC  
17321  
White Europeans  
4429  
Black Europeans (Paris)  
964  
Africans  
508


## White Europeans (n=17,321)




## Black Europeans (n=964)



## Black Africans (n=508)




## White Europeans (n=17,321)




— ASR      ····· AS      - - - - EKFC

## Black Europeans (n=964)



— ASR      - - - - ASR-NB      ····· AS  
- - - - EKFC      — EKFC\*

## Black Africans (n=508)



— ASR      - - - - ASR-NB      ····· AS  
- - - - EKFC      — EKFC\*



# Ethnic, race factors in Africa and Europe

Flamant M et al **RESEARCH LETTER**

**Performance of GFR Estimating Equations in African Europeans: Basis for a Lower Race-Ethnicity Factor Than in African Americans**

# NO



RESEARCH ARTICLE

Performance of glomerular filtration rate estimation equations in Congolese healthy adults: The inopportunity of the ethnic correction

Justine B. Bukabau<sup>1,\*</sup>, Ernest K. Sumaili<sup>1</sup>, Etienne Cavalier<sup>2</sup>, Hans Pottel<sup>3</sup>, Bejos Kifakiou<sup>1</sup>, Aliocha Nkodila<sup>1</sup>, Jean Robert R. Makulo<sup>1</sup>, Vieux M. Mokoli<sup>1</sup>, Chantal V. Zinga<sup>1</sup>, Augustin L. Longo<sup>1</sup>, Yannick M. Engole<sup>1</sup>, Yannick M. Nlandu<sup>1</sup>, François B. Lepira<sup>1</sup>, Nazaire M. Nseka<sup>1</sup>, Jean Marie Krzesinski<sup>4</sup>, Pierre Delanaye<sup>5</sup>

<sup>1</sup> Renal Unit, Department of Internal medicine, Kinshasa University Hospital, University of Kinshasa, Kinshasa, Democratic Republic of the Congo, <sup>2</sup> Division of Clinical Chemistry, CHU Sart Tilman (ULg CHU), University of Liège, Liège, Belgium, <sup>3</sup> Division of Public Health and Primary Care, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium, <sup>4</sup> Division of Nephrology-Dialysis-Transplantation, CHU Sart Tilman (ULg CHU), University of Liège, Liège, Belgium

\* justinebuk@yahoo.fr



**Performance of creatinine- or cystatin C-based equations to estimate glomerular filtration rate in sub-Saharan African populations**



see commentary on page 1017

Justine B. Bukabau<sup>1,7</sup>, Eric Yayo<sup>2,7</sup>, Appolinaire Gnionsahé<sup>3</sup>, Dagui Monnet<sup>2</sup>, Hans Pottel<sup>4</sup>, Etienne Cavalier<sup>5</sup>, Aliocha Nkodila<sup>1</sup>, Jean Robert R. Makulo<sup>1</sup>, Vieux M. Mokoli<sup>1</sup>, François B. Lepira<sup>1</sup>, Nazaire M. Nseka<sup>1</sup>, Jean-Marie Krzesinski<sup>6</sup>, Ernest K. Sumaili<sup>1,7</sup> and Pierre Delanaye<sup>6,7</sup>

<sup>1</sup>Renal Unit, Department of Internal Medicine, Kinshasa University Hospital, University of Kinshasa, Kinshasa, Democratic Republic of Congo; <sup>2</sup>Département de Biochimie, UFR Sciences Pharmaceutiques et Biologiques, Université Felix Houphouët Boigny, Abidjan, Ivory Coast; <sup>3</sup>Département de Néphrologie, UFR Sciences Médicales, Université Felix Houphouët Boigny, Abidjan, Ivory Coast; <sup>4</sup>Department of Public Health and Primary Care, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium; <sup>5</sup>Division of Clinical Chemistry, CHU Sart Tilman (ULg CHU), University of Liège, Liège, Belgium; and <sup>6</sup>Division of Nephrology-Dialysis-Transplantation, CHU Sart Tilman (ULg CHU), University of Liège, Liège, Belgium

Néphrologie & Thérapeutique 12 (2016) 454–459



Disponible en ligne sur  
**ScienceDirect**  
www.sciencedirect.com

Elsevier Masson France  
**EM|consulte**  
www.em-consulte.com



Article original

Inadéquation du facteur ethnique pour l'estimation du débit de filtration glomérulaire en population générale noire-africaine : résultats en Côte d'Ivoire



*Inadequacy of the African-American ethnic factor to estimate glomerular filtration rate in an African general population: Results from Côte d'Ivoire*

Éric Sagou Yayo<sup>a</sup>, Mireille Aye<sup>a</sup>, Jean-Louis Konan<sup>a</sup>, Arlette Emième<sup>b</sup>, Marie-Laure Attoungbre<sup>a</sup>, Appolinaire Gnionsahé<sup>c</sup>, Etienne Cavalier<sup>d</sup>, Dagui Monnet<sup>a</sup>, Pierre Delanaye<sup>e,\*</sup>

*Yayo ES, Nephrol Ther, 2016, 12, 454*  
*Flamant M, Am J Kidney Dis, 2013, 62, 179*  
*Bukabau JB, Kidney Int, 2019, 95, 1181*


Pierre Delanaye<sup>1,2</sup>,  
Hans Pottel<sup>3</sup> and  
Richard J. Glassock<sup>4</sup>

## Americentrism in estimation of glomerular filtration rate equations

*Kidney International* (2022) **101**, 856–858; <https://doi.org/10.1016/j.kint.2022.02.022>

KEYWORDS: glomerular filtration rate; race; serum creatinine

Copyright © 2022, International Society of Nephrology. Published by Elsevier Inc. All rights reserved.



The new CKD-EPI equation is performing worse in Europe  
The previous CKD-EPI equation had to be used without the correction in Europe  
and Africa

- ⇒ Use the CKD-EPI<sub>2009</sub> equation without the ethnic factor or the EKFC equation
- ⇒ All equations should be interpreted with caution in AKI
- ⇒ Finally, it is just a calculation
- ⇒ Probably not the most important in humanitarian situations

# A few words about proteinuria/albuminuria measurement

- For CKD detection/staging
- not very useful in most AKI situations
- Help for urinary infection (leucocytes<sup>+</sup>, nitrites<sup>+</sup>, hematuria)
- Hematuria
- Glucose, Ketones
- Strips: Easy and cheap for the context



# A few words about proteinuria/albuminuria measurement

- For CKD detection/staging
- not very useful in most AKI situations
- Help for urinary infection (leucocytes<sup>+</sup>, nitrites<sup>+</sup>, hematuria)
- Hematuria
- **Glucose, Ketones**
- Strips: Easy and cheap for the context



# Limitations

Journal of Nephrology (2021) 34:411–432  
<https://doi.org/10.1007/s40620-020-00735-y>

REVIEW



## Urinary strips for protein assays: easy to do but difficult to interpret!

Guillaume Réslmont<sup>1</sup> · Laurence Pléroni<sup>2</sup> · Edith Bigot-Corbel<sup>3</sup> · Etienne Cavaller<sup>4</sup> · Pierre Delanaye<sup>1,5</sup>

Received: 23 January 2020 / Accepted: 3 April 2020 / Published online: 23 April 2020  
© Italian Society of Nephrology 2020

### Abstract

Urine samples can be readily obtained from patients in everyday clinical practice. Therefore, the availability of urine allows physicians to obtain relevant clinical information in a timely manner. Since the measurement of urinary protein levels is essential in diagnosing and treating a host of diseases, the potential detection of urinary proteins by urinary strips in an easy, quick, and cheap way is very attractive. However, to ensure optimal use of urinary strips, one needs to be aware of their characteristics and their limitations. In this review, we discuss the characteristics of the urinary strips available for testing urinary protein levels and for detecting urinary albumin. We then consider their analytical performances in their most widely used clinical applications (e.g., in pregnancy, chronic kidney disease, diabetes, and screening of the general population).

**Keywords** Urinary strips · Urinary protein · Urinary albumin · Urinary dipstick · Proteinuria

# Conclusions

- Renal diseases are potentially present in Refugees camps
- We lack of strong data regarding prevalence, incidence
- POC are of interest

**nephron**  
Clinical  
Practice

## Clinical Practice: Review

---

Nephron 2017;136:302–308  
DOI: 10.1159/000469669

Received: December 22, 2016  
Accepted after revision: March 5, 2017  
Published online: April 26, 2017


---

## Serum Creatinine: Not So Simple!

Pierre Delanaye<sup>a</sup> Etienne Cavalier<sup>b</sup> Hans Pottel<sup>c</sup>

<sup>a</sup>Department of Nephrology Dialysis Transplantation, and <sup>b</sup>Department of Clinical Chemistry, University of Liège (CHU ULg), Liège, and <sup>c</sup>Department of Public Health and Primary Care, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium

# Liège



Questions?  
[pdelanaye@chuliege.be](mailto:pdelanaye@chuliege.be)